Advertisement
Singapore markets open in 4 hours 38 minutes

  • Straits Times Index

    3,441.77
    -2.41 (-0.07%)
     

  • S&P 500

    5,436.44
    -27.10 (-0.50%)
     

  • Dow

    40,743.33
    +203.40 (+0.50%)
     

  • Nasdaq

    17,147.42
    -222.79 (-1.28%)
     

  • Bitcoin USD

    65,954.45
    -1,273.40 (-1.89%)
     

  • CMC Crypto 200

    1,341.30
    -29.18 (-2.13%)
     

  • FTSE 100

    8,274.41
    -17.94 (-0.22%)
     

  • Gold

    2,455.10
    +29.60 (+1.22%)
     

  • Crude Oil

    75.18
    -0.63 (-0.83%)
     

  • 10-Yr Bond

    4.1430
    -0.0350 (-0.84%)
     

  • Nikkei

    38,525.95
    +57.32 (+0.15%)
     

  • Hang Seng

    17,002.91
    -235.43 (-1.37%)
     

  • FTSE Bursa Malaysia

    1,611.94
    -12.62 (-0.78%)
     

  • Jakarta Composite Index

    7,241.86
    -7,288.90 (-50.16%)
     

  • PSE Index

    6,606.36
    -42.87 (-0.64%)
     

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant

Vandana Singh
·2-min read

Monday, the FDA informed Mesoblast Limited (NASDAQ:MESO) that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

“We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD,” said Mesoblast CEO Dr. Silviu Itescu.

Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.

In August 2023, the FDA issued a complete response letter to Mesoblast’s resubmission for remestemcel-L for pediatric SR-aGVHD.

The agency required more data, and Mesoblast said it would conduct a targeted, controlled study in the highest-risk adults with the greatest mortality.

While the Oncologic Drugs Advisory Committee of the FDA in August 2020 voted 9:1 in favor of remestemcel-L’s efficacy in a pediatric patient population, in September 2020, the FDA recommended further steps be undertaken to obtain approval.

The BLA resubmission of January 2023 included long-term follow-up data from the Phase 3 trial by the Center for International Blood and Marrow Transplant Research, showing 50% survival through more than four years of follow-up for remestemcel-L treated patients.

Earlier this month, the FDA supported an accelerated approval pathway for rexlemestrocel-L for end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD).

Price Action: MESO shares are up 75.90% at $3.87 on the last check Tuesday.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.